ClinicalTrials.gg
WithdrawnNCT05206591CAIN457X12301Updated Jan 9, 2023

Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).

A Phase 3 interventional study of Secukinumab and Placebo in Active Peripheral Spondyloarthritis (pSpA), sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Trial terminated due to strategic decision of senior management

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the efficacy and safety of subcutaneous (s.c) secukinumab in comparison with placebo for participants with two subtypes of active pSpA i.e. undifferentiated pSpA and chronic reactive arthritis, and with an inadequate response to conventional therapy despite current or previous Non-steroidal Anti Inflammatory Drugs (NSAIDs) and/or csDMARDs. Additionally, the study aims to evaluate efficacy and safety of continuing versus withdrawing secukinumab therapy in maintaining remission in the study population.

Read the detailed description

This is a randomized, parallel-group, double-blind, placebo-controlled, multicenter, Phase III study designed to assess efficacy and safety of secukinumab compared to placebo in adult patients with active pSpA, composed of the subsets of undifferentiated pSpA and chronic reactive arthritis. Approximately 324 eligible participants with pSpA will enroll into the study with approximately 162 participants in each of the double-blind arms. This population will be comprised of approximately 292 participants with undifferentiated pSpA and approximately 32 participants with chronic reactive arthritis.

The participants will be stratified 1:1 ratio at randomization (Baseline) according to:

  • High Sensitivity C-reactive Protein (hsCRP) level: Participants will be equally stratified based on hsCRP (≤5mg/L) or hsCRP (>5 mg/L) as measured at Screening Visit 2 (SV2) with the hsCRP (≤5mg/L) strata capped at 50%.
  • Sub-type of pSpA: Approximately 90% of randomized participants will be diagnosed with undifferentiated pSpA and up to 10% participants with chronic reactive arthritis.

The trial consists of 5 periods: a screening, double-blind treatment, randomized withdrawal, an open label treatment and safety follow-up period, detailed below:

  1. Screening period- Up to 8 weeks to assess participant's eligibility, composed of 2 visits - SV1 and SV2.
  2. Double-blind Treatment period - Baseline (BSL) (Week 0) to Week 56 [Treatment Period 1]

    Eligible participants will be randomized at BSL (Week 0) in a 1:1 ratio to one of the following double-blind arms:

    • Arm 1 (N=162 participants): Secukinumab 300 mg s.c. at Week 0, 1, 2, 3, 4, then every 4 weeks thereafter up to and including Week 52.
    • Arm 2 (N= 162 participants): Placebo s.c. at Week 0, 1, 2, 3, 4, then every 4 weeks thereafter up to and including Week 52.
  3. Randomized Withdrawal- (Week 56 to Week 108) [Treatment Period 2]
  4. Open-label Treatment period- (Week 20 to Week 216) [Treatment Period 3]
  5. Safety Follow-up period - Following the EOT visit at Week 216, there will be an End of Treatment (EOS) visit at Week 224 for safety assessments

The primary endpoint analysis will be performed after all participants have completed the Week 16 visit. The investigators, site personnel and monitors will continue to remain blinded to the original treatment assignment that each participant received at randomization until after the database lock for final analysis.

Analysis Plan A is planned after participants have completed the Week 16 assessments. Analysis Plan B is planned after participants have completed the Week 52 assessments in order to support regulatory submission and/or publication purposes. The analysis at Week 108 will be conducted after all participants complete the Treatment Period 2. The final analysis will be conducted after all participants complete the study. Additional analyses may be performed to support interactions with health authorities, as necessary.

02

Conditions studied

  • Active Peripheral Spondyloarthritis (pSpA)

Keywords

  • secukinumab, active peripheral spondyloarthritis (pSpA)
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed must be obtained prior to participation in the study.
  2. Participant must be able to understand and communicate with the investigator and comply with the requirements of the study.
  3. Male or non-pregnant, non-lactating female participants at least 18 years of age.
  4. Participant meets ASAS criteria for classification of pSpA:

    • Participant must have current arthritis (asymmetric or predominantly in the lower limbs) or enthesitis (except for enthesitis only along the spine
    • , sacroiliac joints and/or chest wall) or dactylitis. AND at least one of the following SpA features:
    • Anterior uveitis in past confirmed by a qualified medical professional (participants with current ongoing uveitis are excluded from participation in the study)
    • Evidence of preceding infection (acute diarrhea or non-gonococcal urethritis or cervicitis 1 month before arthritis)
    • HLA-B27 positivity
    • Sacroiliitis on imaging; based on prior magnetic resonance imaging (MRI) or X-ray OR at least 2 of the following SpA features:
    • Arthritis (past or present diagnosis), adequately documented and identified, or diagnosed by a qualified medical professional
    • Enthesitis (any location, past or present diagnosis), adequately documented and identified, or diagnosed by a qualified medical professional
    • Dactylitis (past or present diagnosis) adequately documented and identified, or diagnosed by a qualified medical professional
    • Inflammatory back pain (past or present) Note: If there is concurrent inflammatory back pain it must be \< 2 on NRS score for total back pain \& nocturnal back pain (score 0-10) and the peripheral symptomatology of pSpA must be the predominant symptoms at study entry, based on the investigator's judgment at baseline.
    • Family history for SpA.
  5. Diagnosis of pSpA with evidence of active disease as manifested by

    • Patient's global assessment of disease activity (0-100 VAS) ≥ 40 mm, and
    • Patient's global assessment of pain (0-100 VAS) ≥ 40 mm, and
    • At least one of the following:
    • ≥ 2 joints that are both tender and swollen
    • ≥ 2 sites of severe enthesitis as assessed by the investigator and ≥ 1 joint that is both tender and swollen
    • ≥ 2 digits with dactylitis and ≥1 joint that is both tender and swollen not associated with dactylitis
  6. Rheumatoid Factor (RF) and Anti-cyclic citrullinated peptides (anti-CCP) antibodies negative at screening.
  7. Duration of symptoms of at least 6 months.
  8. Participant should have been on at least 2 different non-steroidal anti-inflammatory drugs (NSAIDs) at the highest recommended dose for at least 4 weeks in total prior to randomization with an inadequate response or failure to respond, or less if therapy had to be withdrawn due to intolerance, toxicity or .
  9. Participant taking methotrexate (≤ 25 mg/week), or sulfasalazine (≤ 3 g/day), or hydroxychloroquine (≤ 400 mg/day) are allowed to continue their medication and must have taken it for at least 3 months and must be on a stable dose and route of administration for at least 4 weeks prior to randomization. Only one of these csDMARDs can be continued during the study.
  10. Participant on stable MTX must be on folic acid supplementation at randomization. 11.Participant taking systemic must be on a stable dose of ≤ 10 mg/day prednisone or equivalent for at least 2 weeks before randomization.

Exclusion criteria

Exclusion Criteria:

  1. Current or previous diagnosis of :

    • Psoriasis (PsO) and/or nail changes consistent with PsO diagnosed by a qualified medical professional
    • PsA diagnosed by a qualified medical professional
    • Inflammatory bowel disease (IBD) diagnosed by a qualified medical professional
    • axSpA (AS or nr-axSpA) diagnosed by a qualified medical professional
  2. Meets ASAS axSpA criteria as manifested by ALL of:

    a. Inflammatory back pain for at least 3 months b. Onset before 45 years of age c.

    Sacroiliitis on MRI with ≥ 1 SpA feature OR HLA-B-27 positive with ≥2 SpA features

  3. Score of ≥2 on numerical rating scale (NRS)-score for total back pain and nocturnal back pain (score 0-10)
  4. History of a confirmed diagnosis of any inflammatory joint disorder other than pSpA (e.g., rheumatoid arthritis, gouty arthritis, other crystalline arthritis, systemic lupus erythematosus, or any arthritis with onset prior to age 16 years such as juvenile idiopathic arthritis).
  5. Prior exposure to TNF-i's or other biologic immunomodulating agents, or approved
  6. Active ongoing inflammatory diseases other than pSpA that might confound the evaluation of the benefit of secukinumab therapy (e.g., uveitis).
  7. Current or previous diagnosis of fibromyalgia by a qualified medical professional
  8. Diagnosis of synovitis associated with primary osteoarthritis
  9. Diagnosis of septic arthritis, sarcoidosis, seronegative RA, or erosive osteoarthritis
  10. Current severe progressive or uncontrolled disease, which in the judgment of the clinical investigator renders the particpant unsuitable for the trial.
  11. History of liver disease or liver injury indicated by abnormal liver function tests, such as (AST), SGPT/ Alanine transaminase (ALT), Alkaline

    phosphatase (ALP) and serum . The investigator should be guided by the following criteria:

    • Any single parameter may not exceed 2 x the (ULN). A single parameter elevated up to and including 2 x ULN should be re-checked once more as soon as possible, and in all cases, at least prior to randomization, to rule-out laboratory error.
    • If the total bilirubin concentration is increased above 2 x ULN, total bilirubin should be differentiated into the direct and indirect reacting bilirubin. In any case, serum bilirubin should not exceed the value of 1.6 mg/dL (27 µmol/L).
  12. Screening total White Blood Cells (WBC) count \<3,000/μl, or \<100,000/μl or neutrophils \<1,500/μl or \<8.5 g/dl (85 g/L).
  13. Plans for administration of during the study period or 6 weeks prior to randomization.
  14. Significant medical problems or diseases, including but not limited to the following: uncontrolled hypertension (≥160/95 mmHg), congestive heart failure ( status of class III or IV), uncontrolled diabetes, or very poor functional status precluding ability to perform self-care.
  15. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive Human Chorionic Gonadotropin (hCG) laboratory test.
  16. History or evidence of ongoing alcohol or drug abuse, within the last six months before randomization.
  17. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of during dosing of study treatment. Effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post- ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant
    • Barrier methods of contraception: Condom or Occlusive cap (e.g. diaphragm or cervical/vault caps)
    • Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS).

    In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.

    NOTE:

    Women are considered if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms). Women are considered not of child bearing potential if they are post-menopausal or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

    If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the ICF.

  18. Previous treatment with any cell-depleting therapies including but not limited to anti- CD20 or investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti- CD19).
  19. Use of other investigational drugs at the time of enrollment, or within 5 half- lives of enrollment, or within 4 weeks until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations.
  20. Use or planned use of prohibited concomitant medication (see Section 6.2.2).
  21. History of lymphoproliferative disease or any known , or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or (except for skin Bowen's disease, or basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non- invasive malignant colon polyps that have been removed).
  22. Presence of significant medical problems which in the opinion of the investigator will interfere with study participation, including but not limited to the following: participants with severely reduced kidney function (estimated (eGFR) \<29 ml/min/1.73m2).
  23. History of to any of the study drug constituents.
  24. Any medical or psychiatric condition, which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.
  25. Chest X-ray or MRI (at Screening Visit 1) with evidence of ongoing infectious or malignant process obtained within 3 months of screening and evaluated by a qualified physician.
  26. Active systemic infection during the last two weeks (exception: common cold) prior to randomization or any infection that reoccurs on a regular basis.
  27. Underlying conditions (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the participant and/or places the participant at unacceptable risk for receiving an immunomodulatory therapy
  28. Known infection with (HIV), or at screening or randomization.
  29. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold test as indicated in the assessment schedule. Participants with a positive test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the participant has no evidence of active tuberculosis. After active tuberculosis has been excluded, treatment for latent tuberculosis according to local country guidelines must have been initiated prior to enrollment.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Secukinumab

    Secukinumab 300 mg s.c

    Biological: Secukinumab

  • Placebo comparator
    Placebo

    Placebo s.c.

    Other: Placebo

Interventions

  • BiologicalSecukinumab

    Secukinumab 300 s.c.

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Modified Peripheral SpondyloArthritis Response Criteria (mPSpARC)

    To demonstrate the superiority of secukinumab compared to placebo based on Modified Peripheral SpondyloArthritis Response Criteria mPSpARC40

    Time frame: Week 16

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2022; primary completion for Mar 2028, 67 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2022
First posted
Jan 25, 2022
StartEst.
Aug 16, 2022
Primary completionEst.
Mar 20, 2028
CompletionEst.
Jun 12, 2028
Last update
Jan 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05206591
Responsible party
Sponsor
First posted
Jan 25, 2022
Start date
Aug 16, 2022 (estimated)
Primary completion
Mar 20, 2028 (estimated)
Completion
Jun 12, 2028 (estimated)
Last update
Jan 9, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion